ClearPoint Neuro files financials for acquired IRRAS; IRRAS cash from ops -$11.4M in 2024

ClearPoint Neuro, Inc.

IRRAS 2024 operating cash outflow $11.4M; accumulated deficit $105.3M.
Gross accounts receivable $1.67M with $22.5K credit loss allowance.
Convertible notes of $6.33M at 5% interest; fair value adjustment recorded $219.6K expense.

item 9.01

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-039470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.